Literature DB >> 19741612

Bristol-Myers Squibb swallows last of antibody pioneers.

Malorye Allison.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19741612     DOI: 10.1038/nbt0909-781

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

  1 in total
  6 in total

1.  Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall.

Authors:  Emma Dorey
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

2.  p38 kinase inhibitor approved for idiopathic pulmonary fibrosis.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2011-04       Impact factor: 54.908

Review 3.  Protein-protein interaction modulators: advances, successes and remaining challenges.

Authors:  Lloyd Mabonga; Abidemi Paul Kappo
Journal:  Biophys Rev       Date:  2019-07-12

4.  BMS bets on targeting IL-8 to enhance cancer immunotherapies.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

5.  Cautious optimism surrounds early clinical data for PD-1 blocker.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908

6.  Industry pursues co-stimulatory receptor immunomodulators to treat cancer.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.